Denmark· DK-28107163624
Imreplys
A sargramostim product containing sargramostim, registered in Denmark by Partner Therapeutics Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Sargramostim is registered in 11 of 19 countries.
Countries holding a registration under ATC L03AA09 (sargramostim), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Sargramostim · ATC L03AA09
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- SARGRAMOSTIM
- Manufacturer
- Partner Therapeutics Limited
- Country
- Denmark (DK)
- ATC code
- L03AA09
- ATC class
- Sargramostim
- Defined daily dose
- 0.45 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107163624
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
191 interactions on record for sargramostim.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sargramostim · interactions on record
191 records
- 2 severe
- 189 moderate
Most severe, free to view
- CladribineL01BB04severe
- CyclophosphamideL01AA01moderate
- ChlorambucilL01AA02moderate
- MelphalanL01AA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L03AA09
Sargramostim, as other registers publish it.
- PolandImreplysPartner Therapeutics Ltd.
- FinlandImreplysPartner Therapeutics Limited
- IcelandImreplysPartner Therapeutics Limited
- CzechiaIMREPLYSPartner Therapeutics Ltd., Dublin
- NetherlandsImreplys 250 microgram poeder voor oplossing voor injectiePartner Therapeutics Limited
- IrelandImreplys 250 microgram powder for solution for injectionPartner Therapeutics Limited
- BelgiumImreplys 250 µgPartner Therapeutics
- United StatesLeukinePartner Therapeutics, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7379e340-b17f-498e-bae2-2d18394d5e69 GET /v1/drugs/7379e340-b17f-498e-bae2-2d18394d5e69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til injektionsvæske, opløsning",
"source": "dkma",
"strength": "250 mikrogram",
"auth_role": "MOD",
"dk_drugid": "28107163624",
"substance": "SARGRAMOSTIM",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "45890"
}See everything about sargramostim.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.